Featured Research

from universities, journals, and other organizations

New drug technology produces marked improvement in hepatitis C therapy in animals

Date:
December 3, 2009
Source:
Southwest Foundation for Biomedical Research
Summary:
In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment.

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

Related Articles


The drug, SPC3649, was developed by the biopharmaceutical firm Santaris Pharma A/S in Denmark using their proprietary nucleic acid chemistry called "locked nucleic acid" or LNA. SPC3649 is a nucleic acid, or DNA-based drug, that captures a small RNA molecule in the liver, called microRNA122, that is required for HCV replication.

"Our collaboration with Santaris Pharma proved that the drug worked exceptionally well in treating HCV infections in chimpanzees," said SFBR's Robert Lanford, Ph.D., the lead author on the study appearing in the December 3, 2009 issue of Science Express, which provides rapid electronic publication of research papers ahead of print in the journal Science.

SPC3649 also showed a high barrier to resistance, a major problem with therapies that directly target the virus. Moreover, this proof of concept study suggests that the technology might also prove useful in treating many other diseases such as HIV, cancer, and inflammatory diseases.

HCV infections affect 170 million people worldwide and progress over years to end stage liver disease including cirrhosis and liver cancer. In the United States, 4 percent of the adult population is chronically infected with HCV. The only U.S. Food and Drug Administration approved therapy is interferon and ribavirin, which is very toxic, requires 48 weeks of treatment and works in less than half of patients. Scientists believe that a cocktail of three drugs will be needed to prevent antiviral resistance and replace interferon.

The new therapy could potentially replace interferon in future cocktails, since it provides a high barrier to resistance. "This antiviral could be used alone to treat disease progression and there are indications that it can convert interferon non-responders to responders, so that non-responders to the current therapy could be treated with the combination of this drug with interferon," Lanford said. It may also be a good therapy to use after transplant, since it may help suppress HCV in the new liver. It has no toxic or adverse reactions and this is critical in the transplant setting.

In the study, four HCV chronically infected chimpanzees were treated with the new antiviral. The two animals that received the higher dose had a drop in viral levels in the blood and liver of 2.5 orders of magnitude or approximately 350 fold. The surprising findings were the lack of antiviral resistant mutants and the fact that the therapy continued to work for several months after dosing stopped.

In one advance, the new study was a critical proof of concept that the LNA technology could work for HCV. It proved that miR-122 was truly required for HCV replication in an animal infected with HCV. Previously the role of miR-122 in HCV replication had only been shown in tissue culture. A second advance was the finding that LNA therapy could work against an important disease model, suggesting that the new technology can be applied to other diseases.


Story Source:

The above story is based on materials provided by Southwest Foundation for Biomedical Research. Note: Materials may be edited for content and length.


Cite This Page:

Southwest Foundation for Biomedical Research. "New drug technology produces marked improvement in hepatitis C therapy in animals." ScienceDaily. ScienceDaily, 3 December 2009. <www.sciencedaily.com/releases/2009/12/091203141852.htm>.
Southwest Foundation for Biomedical Research. (2009, December 3). New drug technology produces marked improvement in hepatitis C therapy in animals. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2009/12/091203141852.htm
Southwest Foundation for Biomedical Research. "New drug technology produces marked improvement in hepatitis C therapy in animals." ScienceDaily. www.sciencedaily.com/releases/2009/12/091203141852.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins